Navigation Links
Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
Date:2/25/2011

ated expenses.  The lower costs also resulted from higher prior year expenses associated with preparation for the June 2009 FDA Advisory Committee meeting for KRYSTEXXA, coupled with the wind down of the open label extension clinical trial for KRYSTEXXA.  

Selling, general and administrative expenses decreased $5.8 million, or 19%, to $25.0 million for the year ended December 31, 2010, from $30.8 million for the year ended December 31, 2009.  The decrease was partially due to lower marketing costs, which included $2.1 million of lower expenses associated with the preparation for a possible commercial launch of KRYSTEXXA in 2009 and a decrease of $2.3 million in compensation related and severance expenses.

Other expense, net increased $5.2 million, or 43%, to $17.3 million for the year ended December 31, 2010 as compared to $12.1 million for the year ended December 31, 2009, primarily due to the variance in non-cash mark-to-market valuation adjustments to the Company's warrant liability in 2010 versus the prior year.

Conference CallSavient's management team will host a live conference call and webcast on Friday, February 25, 2011 at 9:00 a.m. Eastern Time to review the fourth quarter and year-end 2010 financial results.  To participate by telephone, please dial 888-357-3694 (Domestic) or 973-890-8276 (International).  The conference identification number is 45733606.  The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.  Please log on to Savient's website 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on February 25, 2011 through 11:59 p.m. Eastern Time on March 11, 2011 by dialing 800-642-1687 (Domestic) or 706-645-9291 (International) and entering conference ID number
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
2. Savient Closes Sale of $230 Million in Convertible Senior Notes
3. Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
4. Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
5. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
6. Savient Pharmaceuticals Announces Search for CEO
7. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results
9. Savient Pharmaceuticals to Hold Third Quarter 2010 Financial Results Conference Call on Friday, November 5, 2010
10. Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
11. Savient Pharmaceuticals Provides Update on Strategic Alternatives Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  HyGreen, Inc., a leader in hand ... with RCA Medical, a subsidiary of Ascendis Health Limited, ... Each year, hundreds of millions of patients around ... organisms are transmitted from patient to patient via the ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), ... extracorporeal cytokine adsorber to reduce deadly inflammation in ... of $385,642, net of transaction costs, in non-dilutive ... Business Tax Certificate Transfer Program sponsored by the ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
(Date:1/22/2015)... 22, 2015 Joan Lunden, award-winning American ... at the upcoming 32nd Annual Miami Breast Cancer ... Education Resource®, LLC (PER®) , shares that “a fast-growing, ... undetected if she had not followed up her clean ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... As interest in the value of spiritual ... worldwide, Rev. Eric J. Hall , president and CEO ... will be the keynote speaker on January 27 at an ... system. , The conference, “Hope and Resilience: Innovative and Interdisciplinary ...
(Date:1/22/2015)... Step into a macabre world where plants hold ... Wicked Plants, the Museum’s latest featured exhibition, opens Saturday, ... and diabolical plants inside of a dilapidated, Victorian home. ... physical and neurological processes between botanicals and the human ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... with chronic obstructive pulmonary disease (COPD) who are hospitalized ... decreased mortality when compared to those who are not ... almost 16,000 COPD patients admitted to VA hospitals. ... edition of the American Thoracic Society,s American Journal ...
... FRIDAY, April 15 (HealthDay News) -- Is estrogen breast cancer,s ... Journal of the American Medical Association , which analyzed data ... when it found a reduced risk of breast cancer in ... This seemed to contradict years of cautions that estrogen therapy ...
... , FRIDAY, April 15 (HealthDay News) -- Losing weight can ... obese, but not all diet plans are effective in lowering ... against cancer are those that encourage long-term changes in eating ... food groups, explained Daxaben Amin, a senior clinical dietitian in ...
... New York, N.Y. (April 15, 2011) A comprehensive ... Autism Tissue Program (ATP), a postmortem brain tissue donation ... autism also had epilepsy, and co-morbidity data from the ... than expected rate of mortality in individuals with both ...
... HealthDay Reporter , THURSDAY, April 14 (HealthDay News) -- Seniors ... with their neighbors stand a much better chance of surviving ... each increase in what researchers call neighborhood "cohesion," such as ... on a neighbor for help, the odds of survival after ...
... elective surgery reduces potentially serious kidney complications, according to ... Journal of the American Society Nephrology (JASN). ... surgeries are performed around the world. Unfortunately, many patients ... surgery, often due to decreased blood flow to the ...
Cached Medicine News:Health News:Large study finds ICS therapy reduces pneumonia mortality 2Health News:Estrogen's Role in Breast Cancer Can Fluctuate 2Health News:Estrogen's Role in Breast Cancer Can Fluctuate 3Health News:A Good Diet Includes Many Cancer-Fighting Foods: Expert 2Health News:Mortality rate is increased in persons with autism who also have epilepsy 2Health News:Close-Knit Neighborhoods Raise Chances of Stroke Survival 2Health News:Statins may protect against kidney complications following elective surgery 2
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Medicine Products: